{"organizations": [], "uuid": "a439ce076fad027011d64531716ac6a3e1fe0c8c", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-orexigen-therapeutics-enters-agree/brief-orexigen-therapeutics-enters-agreement-for-sale-of-co-idUSFWN1S00ZO", "country": "US", "domain_rank": 408, "title": "BRIEF-Orexigen Therapeutics Enters Agreement For Sale Of Co", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-23T20:32:00.000+03:00", "replies_count": 0, "uuid": "a439ce076fad027011d64531716ac6a3e1fe0c8c"}, "author": "", "url": "https://www.reuters.com/article/brief-orexigen-therapeutics-enters-agree/brief-orexigen-therapeutics-enters-agreement-for-sale-of-co-idUSFWN1S00ZO", "ord_in_thread": 0, "title": "BRIEF-Orexigen Therapeutics Enters Agreement For Sale Of Co", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-orexigen therapeutics", "sentiment": "negative"}, {"name": "brief-orexigen therapeutics enters agreement for sale of co", "sentiment": "negative"}, {"name": "ale of co reuters", "sentiment": "none"}, {"name": "nalpropion pharmaceuticals", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "orexigen therapeutics inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 23, 2018 / 5:32 PM / Updated 27 minutes ago BRIEF-Orexigen Therapeutics Enters Agreement For Sale Of Co Reuters Staff April 23 (Reuters) - Orexigen Therapeutics Inc: * OREXIGEN THERAPEUTICS, INC. ENTERS AGREEMENT FOR SALE OF COMPANY * OREXIGEN THERAPEUTICS INC - ENTERED INTO ASSET PURCHASE DEAL WITH NALPROPION PHARMACEUTICALS, TO SELL SUBSTANTIALLY ALL OF ASSETS OF CO * OREXIGEN THERAPEUTICS INC - WILL SELL WORLD-WIDE RIGHTS TO CONTRAVE /MYSIMBA AND CERTAIN OTHER OREXIGEN ASSETS FOR $75 MILLION IN CASH * OREXIGEN THERAPEUTICS- NALPROPION PHARMACEUTICALS IS A NEWLY FORMED SPECIAL PURPOSE ENTITY CAPITALIZED BY INVESTOR GROUP INCLUDING PERNIX THERAPEUTICS Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-04-23T20:32:00.000+03:00", "crawled": "2018-04-23T20:52:50.013+03:00", "highlightTitle": ""}